Call for Abstracts
Advanced Assay Technologies for Drug Discovery
A Conference at BiOS '99, the SPIE International Biomedical Optics
Symposium
22-29 January 1999, San Jose, California
Screening for new pharmaceutical drugs today comprises a triad:
targets, compounds, and assays. Genomics and combinatorial chemistry
are increasing the range of biological targets and compounds available
at a rate that threatens to overwhelm the capacity of existing assays.
In response, there is an unprecedented burst of activity in the
creation of new types of assays. The goals include increased
throughput, miniaturization to minimize sample consumption, and the
ability to monitor biological phenomena beyond the traditional areas
of ligand binding and enzyme activity. These assay systems are being
employed in the drug-discovery process from the high-throughput
primary screening of large libraries through more information-rich
secondary screening and now even to in-vitro tests of properties such
as bioavailability, metabolism, and toxicity. Topics for the
conference include, but are not limited to, strategies based on:
* Analysis of fluorescence (intensity, lifetime, polarization,
fluctuations)
* Chemiluminescence, bioluminescence, and scintillation detection
* Imaging, including macroscopic and microscopic fields
* Micro-chips, micro-fluidics, and optical detection
* Detection of transient signals (e.g., intracellular ion
concentrations) in high-throughput mode
What is SPIE? What is BiOS '99?
SPIE is the International Society for Optical Engineering. BiOS '99
is the premier technical forum for presenting R&D advances and new
applications results in biomedical optics and is part of Photonics
West, the largest lasers, electro-optics, and imaging event in North
America. Photonics West comprises international technical symposia,
continuing education programs, and a diversified technical product
exhibition that drew 10,600 attendees in 1998. See SPIE's web site:
www.spie.org/info/pw/.
Advanced Assay Technologies for Drug Discovery is one of about 35
conferences at BiOS '99, including:
Advanced Assay Technologies for Drug Discovery is one of about 35
conferences at BiOS '99, including:
* Advances in Fluorescence Sensing Technology
* Multidimensional Spectroscopy
* Advances in Nucleic Acid Monitoring, Manipulation and Sequencing
Technologies
* Advanced Techniques in Analytical Cytology
* Micro- and Nano-Fabricated Structures and Devices for Biomedical and
Environmental Applications
* Scanning and Force Microscopies for Biomedical Applications
Submission of Abstracts:
Each abstract should contain the following:
1) Conference (in this case Advanced Assay Technologies for Drug
Discovery, BO28, Owicki)
2) Abstract title
3) Author listing: Given name, family name, affiliation, mailing
address, telephone, fax, and email addresses
4) Type of presentation preferred, oral or poster. At this point we
plan to have oral presentations for sure; there may be posters.
Placement is subject to chair's discretion.
5) Abstract text, about 250 words
6) Keywords, maximum of five
7) Brief biography of principal author, about 50 words
Abstracts are solicited from all types of organizations. Those from
commercial companies should be research oriented rather than product
promotions. Abstracts are due 29 June 98.
There are four ways to submit your abstract.
1) Fill in the form on the SPIE web site
(www.spie.org/forms/pw99b_submission_form.html)
2) Email each abstract separately to abstracts at spie.org in ASCII text
(not encoded). IMPORTANT: to insure receipt and proper processing of
your abstract, the Subject line must include only the following:
BO28, OWICKI.
3) Mail three copies of your abstract to: BiOS '99, SPIE, 1000 20th.
St., Bellingham, WA 98225, USA
4) Fax a copy to SPIE at +1-360-647-1445
Papers:
SPIE publishes a proceedings volume for which speakers are strongly
encouraged to submit short papers based on their talks. The deadline
for camera-ready manuscripts is 28 December 98.
For More Information:
For further information on the conference and on abstract submission,
please contact SPIE at +1 360 676 3290 (tel), +1 360 647 1445 (fax),
or http://www.spie.org/web/meetings/calls/pw99/confs/bo28.html.
Alternatively, please contact Jack Owicki (conference chair) at: +1
408 541 8790 (tel), +1 408 541 8786 (fax) or email
jowicki at ljlbio.com.
